AbCellera Biologics (8QQ) Price & Analysis

Compare

2 Followers

8QQ Stock Chart & Stats

€2.80

-€0.38(-11.28%)

At close: Jan 08 4:00 PM EST

€2.80

-€0.38(-11.28%)

Day’s Range― - ―

52-Week Range€1.70 - €5.78

Previous CloseN/A

Volume0.00

Average Volume (3M)1.04K

Market Cap

€796.85M

Enterprise Value€969.04M

Total Cash (Recent Filing)€495.67M

Total Debt (Recent Filing)€142.22M

Price to Earnings (P/E)―

Beta1.04

Next Earnings

Feb 24, 2026

EPS Estimate

-0.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.16

Shares Outstanding299,335,050

10 Day Avg. Volume911

30 Day Avg. Volume1,038

Financial Highlights & Ratios

PEG Ratio-0.68

Price to Book (P/B)0.82

Price to Sales (P/S)29.91

P/FCF Ratio-4.61

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Market Opportunity For ABCL635Analysts highlight that ABCL635 targeting the vasomotor symptoms market could generate substantial revenues even with a modest market share.

Pipeline BreadthInternal pipeline includes two antibody therapeutics, providing multiple development opportunities and increasing the chance of producing a commercial product.

Strategic Shift To Proprietary DevelopmentAnalysts note a strategic shift toward the internal pipeline that could increase long-term value capture by prioritizing proprietary drug development over partner-dependent programs.

Bears Say

Partnered Business Valuation DeclineValuation for the partnered business has been reduced after substantially fewer partnered programs advanced to the clinic than initially expected, which could lower near-term revenue prospects.

Speculative Investment RiskAnalysts label the stock as speculative, indicating elevated uncertainty that may reduce investor appetite and amplify share price volatility.

Target Engagement UncertaintyUncertainty whether sufficient antibody reaches KNDy neurons for ABCL635 creates a key clinical risk that could delay or derail development progress.

AbCellera Biologics News

AbCellera doses first patients in Phase 2 portion of ABCL635 trial

AbCellera (ABCL) announced that the first patients have been dosed in the Phase 2 portion of its ongoing...

1M ago

ABCL

Viking Therapeutics names Neil Aubuchon as Chief Commercial Officer

Viking Therapeutics (VKTX) announced the appointment of Neil Aubuchon as chief commercial officer. Aubuchon brings more than two...

2M ago

ABCL

VKTX

AbCellera Secures Global Settlement and Patent License Deal

AbCellera Biologics ( ($ABCL) ) has shared an announcement. On December 18, 2025, AbCellera Biologics announced a global...

2M ago

ABCL

AbCellera to receive $36M upfront in patent litigation settlement with Bruker

AbCellera (ABCL) announced that it has entered into a settlement and patent license agreement with Bruker Corporation (BRKR),...

2M ago

ABCL

BRKR

Strategic Shift and Promising Antibody Therapeutics Drive Buy Rating for AbCellera Biologics

In a report released yesterday, David Martin PhD from Bloom Burton maintained a Buy rating on AbCellera Biologics,...

3M ago

ABCL

AbCellera Appoints Dr. Stephen Quake to Board

AbCellera Biologics ( ($ABCL) ) has issued an announcement. On November 10, 2025, AbCellera Biologics announced the appointment...

3M ago

ABCL

AbCellera Biologics’ Earnings Call: Key Insights

Abcellera Biologics, Inc. (($ABCL)) has held its Q3 earnings call. Read on for the main highlights of the...

3M ago

ABCL

3 Best Stocks to Buy Now, 11/7/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

4M ago

ABCL

BLND

AbCellera downgraded to Market Perform from Outperform at Leerink

Leerink downgraded AbCellera (ABCL) to Market Perform from Outperform with a $4 price target Published first on TheFly...

4M ago

ABCL

AbCellera Biologics Reports Q3 2025 Financial Results

Abcellera Biologics, Inc. ( ($ABCL) ) has released its Q3 earnings. Here is a breakdown of the information...

4M ago

ABCL

AbCellera Biologics Reports Q3 2025 Financial Results

AbCellera Biologics ( ($ABCL) ) has provided an announcement. AbCellera Biologics reported its financial results for the third...

4M ago

ABCL

AbCellera reports Q3 EPS (19c), consensus (16c)

Reports Q3 Liquidity of $523 million of total cash, cash equivalents, and marketable securities and approximately $159 million...

4M ago

ABCL

AbCellera’s ABCL635 Study: A Promising Step for Menopause Treatment

Abcellera Biologics, Inc. (($ABCL)) announced an update on their ongoing clinical study. AbCellera Biologics Inc. is conducting a...

4M ago

ABCL

AbCellera’s Phase 1 Study of ABCL575: A Potential Game-Changer?

Abcellera Biologics, Inc. (($ABCL)) announced an update on their ongoing clinical study. AbCellera Biologics Inc. is conducting a...

4M ago

ABCL

8QQ FAQ

What was Abcellera Biologics, Inc.’s price range in the past 12 months?

Abcellera Biologics, Inc. lowest stock price was €1.70 and its highest was €5.78 in the past 12 months.

What is Abcellera Biologics, Inc.’s market cap?

Abcellera Biologics, Inc.’s market cap is €796.85M.

When is Abcellera Biologics, Inc.’s upcoming earnings report date?

Abcellera Biologics, Inc.’s upcoming earnings report date is Feb 24, 2026 which is in 2 days.

How were Abcellera Biologics, Inc.’s earnings last quarter?

Abcellera Biologics, Inc. released its earnings results on Nov 06, 2025. The company reported -€0.161 earnings per share for the quarter, missing the consensus estimate of -€0.118 by -€0.043.

Is Abcellera Biologics, Inc. overvalued?

According to Wall Street analysts Abcellera Biologics, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Abcellera Biologics, Inc. pay dividends?

Abcellera Biologics, Inc. does not currently pay dividends.

What is Abcellera Biologics, Inc.’s EPS estimate?

Abcellera Biologics, Inc.’s EPS estimate is -0.11.

How many shares outstanding does Abcellera Biologics, Inc. have?

Abcellera Biologics, Inc. has 299,335,050 shares outstanding.

What happened to Abcellera Biologics, Inc.’s price movement after its last earnings report?

Abcellera Biologics, Inc. reported an EPS of -€0.161 in its last earnings report, missing expectations of -€0.118. Following the earnings report the stock price went down -21.429%.

Which hedge fund is a major shareholder of Abcellera Biologics, Inc.?

Currently, no hedge funds are holding shares in DE:8QQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

AbCellera Biologics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-16.81%

Trailing 12-Months

Asset Growth

-2.64%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Abcellera Biologics, Inc.

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics (8QQ) Earnings & Revenues

Historic Earnings Reports

8QQ Company Deck

8QQ Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlights AbCellera's successful transition to a clinical-stage biotech and strong liquidity position, but also notes increased net loss and R&D expenses. While revenue has increased, the stagnation in partner-initiated programs presents a challenge.View all DE:8QQ earnings summaries

8QQ Revenue Breakdown

93.51% Research fees

3.94% Royalty revenue

2.55% Milestone payments

8QQ Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","5":"€5","-1":"-€1","0.5":"€0.5","3.5":"€3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.104,2.8652307692307692,2.6264615384615384,2.3876923076923076,2.1489230769230767,1.910153846153846,1.6713846153846155,1.4326153846153846,1.1938461538461538,0.9550769230769229,0.7163076923076921,0.47753846153846125,0.23876923076923084,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.104,2.8652307692307692,2.6264615384615384,2.3876923076923076,2.1489230769230767,1.910153846153846,1.6713846153846155,1.4326153846153846,1.1938461538461538,0.9550769230769229,0.7163076923076921,0.47753846153846125,0.23876923076923084,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.104,2.8652307692307692,2.6264615384615384,2.3876923076923076,2.1489230769230767,1.910153846153846,1.6713846153846155,1.4326153846153846,1.1938461538461538,0.9550769230769229,0.7163076923076921,0.47753846153846125,0.23876923076923084,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.144,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.494,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.979,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.209,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.747,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.591,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.379,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.632,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.104,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >